Abstract

Objectives: 1. Link hair follicle stem cell biology to a practical clinical concept of androgenetic alopecia as impaired activation, where resident stem cells persist but are functionally blocked. 2. Present autologous cellular micrografting as a clinic friendly regenerative approach. 3. Review clinical evidence and provide actionable guidance on patient selection, expectations, and combination strategies Introduction: Androgenetic alopecia is highly prevalent and chronic, and management is often constrained by medication side effects and long term adherence, creating a strong need for regenerative, clinic friendly options. This session frames AGA as impaired activation rather than complete stem cell loss. Materials / method: Autologous cellular micrografting is presented as a minimally invasive same procedure technique that mechanically disaggregates small scalp punches into a progenitor rich suspension containing epithelial progenitors, mesenchymal progenitors, ECM microfragments, and native trophic factors or extracellular vesicles, followed by immediate reinjection into thinning areas without culture expansion. Evidence is reviewed from a single center retrospective cohort of 140 adults (Sinclair 2 to 4 females, Norwood 2 to 3 males), evaluated one to six months post treatment using digital trichometry. Results: Two thirds of patients demonstrated a favorable change in cumulative hair thickness (63.6 to 66.4 percent, mean plus 1.2 to 1.4 mm per cm squared), translating into improved scalp coverage and noticeable cosmetic benefit. Conclusion: Hair follicle stem cell biology supports a clinically useful model of AGA as a state of impaired activation, and cohort data suggest autologous cellular micrografting can produce measurable improvements in hair thickness in a meaningful proportion of patients. Attendees will leave with clear selection pearls, realistic expectations including non responders, and combination strategies to maximize outcomes in daily practice.